Download full-text PDF

Source

Publication Analysis

Top Keywords

[experimental carcinoma
4
carcinoma stomach
4
stomach author's
4
author's transl]
4
[experimental
1
stomach
1
author's
1
transl]
1

Similar Publications

Background: Lenvatinib is an oral tyrosine kinase inhibitor that selectively inhib-its receptors involved in tumor angiogenesis and tumor growth. It is an emerging first-line treatment agent for hepatocellular carcinoma (HCC). However, there is no intravenous ad-ministration of Lenvatinib.

View Article and Find Full Text PDF

Assessment of Surgical Margin of Tongue Squamous Cell Carcinoma via Raman Mapping.

Oral Dis

January 2025

State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Department of Head and Neck Oncology Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.

Objectives: This study introduces a novel classification approach that combines convolutional neural network (CNN) and Raman mapping to differentiate between tongue squamous cell carcinoma (TSCC) and non-tumorous tissue, as well as to identify different histological grades of TSCC.

Materials And Methods: In this study, 240 Raman mappings data from 30 tissue samples were collected from 15 patients who had undergone surgical resection for TSCC. A total of 18,000 sub-mappings extracted from Raman mappings were then used to train and test a CNN model, which extracted feature representations that were subsequently processed through a fully connected network to perform classification tasks based on the Raman mapping data.

View Article and Find Full Text PDF

Background: The lack of predictive biomarkers contributes notably to the poor outcomes of patients with pancreatic ductal adenocarcinoma (PDAC). Cancer-associated fibroblasts (CAFs) are the key components of the prominent PDAC stroma. Data on clinical relevance of CAFs entering the bloodstream, known as circulating CAFs (cCAFs) are scarce.

View Article and Find Full Text PDF

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9.

Respir Res

January 2025

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

H3 lysine 4 trimethylation (H3K4me3) modification and related regulators extensively regulate various crucial transcriptional courses in health and disease. However, the regulatory relationship between H3K4me3 modification and anti-tumor immunity has not been fully elucidated. We identified 72 independent prognostic genes of lung adenocarcinoma (LUAD) whose transcriptional expression were closely correlated with known 27 H3K4me3 regulators.

View Article and Find Full Text PDF

Background: Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting agent, such as the humanized anti-GPC3 antibody GC33 (condrituzumab), could be attached to their surface. Here, we investigated the use of idarubicin-loaded CS-NBs for HCC treatment and a GC33-derived minibody (that we named 4A1) to enhance CS-NB delivery.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!